Skip to main content

Callicutt Jack W's Form 4 filing

Galectin Therapeutics Inc (GALT) · filed Jan 6, 2026

Accession no.
0001133416-26-000006
Filed
Jan 6, 2026
Trade date
Jan 1-6, 2026
Filing delay
5 daysLate
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $233.5K. It was filed 5 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Callicutt Jack WCIK 0001266773Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 2, 2026Common StockMOption exerciseAcquired+60,000$0.00F3$067,614Direct
Jan 2, 2026Common StockSSaleDisposed−13,914$4.20F2−$58,438.853,700Direct
Jan 5, 2026Common StockSSaleDisposed−25,732$3.90F5−$100,354.827,968Direct
Jan 6, 2026Common StockSSaleDisposed−20,354$3.67F6−$74,699.187,614Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 1, 2026Common StockMOption exerciseDisposed−60,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F3

Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.

Referenced by the price of 1 transaction in Table I.

F5

The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F6

The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)